
Keywords: Cyps; cyclophilins; CypA; cyclophilin A; PPIases; peptidyl-prolyl isomerases; CsA; cyclosporin A; HIV-1; human immunodeficiency virus 1; HCV; hepatitis C virus; SBDD; structure-based drug design; FBDD; fragment-based drug discovery; MD; molecular dynami